Center-Authored Papers

Filters: Author is van Rhee, Frits  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2009
Zhou Y, Nair B, Shaughnessy JD, Cartron M-A, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B.  2009.  Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.. British journal of haematology. 145(5):637-41. Abstract
Hoering A, Crowley J, Shaughnessy JD, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E et al..  2009.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.. Blood. 114(7):1299-305. Abstract
Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J et al..  2009.  TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.. British journal of haematology. 147(3):347-51. Abstract
Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J et al..  2009.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.. Blood. 114(10):2068-76. Abstract
2010
Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD, Szymonifka J, Hoering A, Petty N, Crowley J.  2010.  Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3023-7. Abstract
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BGM, Harousseau J-L.  2010.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(7):1209-14. Abstract
Nair B, van Rhee F, Shaughnessy JD, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.  2010.  Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.. Blood. 115(21):4168-73. Abstract
van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al..  2010.  Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(23):3701-8. Abstract
van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD, Hoering A, Crowley J et al..  2010.  Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.. Blood. 116(8):1220-7. Abstract
2011
Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E et al..  2011.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3.. Blood. 118(13):3512-3524. Abstract
Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.  2011.  International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.. Cancer. 117(5):1001-9. Abstract
Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DEH, Singhal AK.  2011.  A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.. Blood. 120(3):552-559. Abstract
2013
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ et al..  2013.  Risk Factors for MDS and Acute Leukemia Following Total Therapy 2 and 3 for Multiple Myeloma.. Blood. Abstract
Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D, Keller J, Waheed S, Usmani SZ, van Rhee F et al..  2013.  Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.. Haematologica. 98(7):1147-53. Abstract
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F et al..  2013.  Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with Total Therapy 3.. Blood. Abstract
Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S et al..  2013.  A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
2014
van Rhee F, Wong RS, Munshi N, Rossi J-F, Ke X-Y, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK et al..  2014.  Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.. The lancet oncology. 15(9):966-74. Abstract
Adult
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BGM, Harousseau J-L.  2010.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(7):1209-14. Abstract
van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al..  2010.  Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(23):3701-8. Abstract
Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E et al..  2011.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3.. Blood. 118(13):3512-3524. Abstract
Age of Onset
Hoering A, Crowley J, Shaughnessy JD, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E et al..  2009.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.. Blood. 114(7):1299-305. Abstract
Aged
Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.  2011.  International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.. Cancer. 117(5):1001-9. Abstract
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BGM, Harousseau J-L.  2010.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(7):1209-14. Abstract
van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al..  2010.  Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(23):3701-8. Abstract
Zhou Y, Nair B, Shaughnessy JD, Cartron M-A, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B.  2009.  Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.. British journal of haematology. 145(5):637-41. Abstract